Literature DB >> 28943324

The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.

Lisa H Butterfield1.   

Abstract

The clinical successes in cancer immunotherapy have led to a critical need for biomarkers in cancer immunotherapy. It is of the utmost importance to know who is most likely to benefit from these therapies (predictive biomarkers) but also who is starting to respond (prognostic biomarkers) and how the therapy functions in order to make rational combination choices (mechanism of action biomarkers). The Society for Immunotherapy of Cancer (SITC) Biomarkers Task Force addressed the state of the art and made a series of recommendations for the field, which is summarized here.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Checkpoint blockade; Flow cytometry; Sequencing; Standardization; Validation

Mesh：

Substances：

Year:  2017        PMID： 28943324      PMCID： PMC5862764          DOI： 10.1016/j.semcancer.2017.09.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  33 in total

1.  Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.

Authors:  Michael T Lotze; Ena Wang; Francesco M Marincola; Nabil Hanna; Peter J Bugelski; Christine A Burns; George Coukos; Nitin Damle; Tony E Godfrey; W Martin Howell; Monica C Panelli; Michael A Perricone; Emanuel F Petricoin; Guido Sauter; Carmen Scheibenbogen; Steven C Shivers; D Lansing Taylor; John N Weinstein; Theresa L Whiteside
Journal:  J Immunother       Date:  2005 Mar-Apr       Impact factor: 4.456

Review 2.  Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Authors:  Lisa H Butterfield; A Karolina Palucka; Cedrik M Britten; Madhav V Dhodapkar; Leif Håkansson; Sylvia Janetzki; Yutaka Kawakami; Thomas-Oliver Kleen; Peter P Lee; Cristina Maccalli; Holden T Maecker; Vernon C Maino; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Graham Pawelec; Douglas M Potter; Licia Rivoltini; Lupe G Salazar; Dolores J Schendel; Craig L Slingluff; Wenru Song; David F Stroncek; Hideaki Tahara; Magdalena Thurin; Giorgio Trinchieri; Sjoerd H van Der Burg; Theresa L Whiteside; Jon M Wigginton; Francesco Marincola; Samir Khleif; Bernard A Fox; Mary L Disis
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.

Authors:  Lisa H Butterfield; Mary L Disis; Samir N Khleif; James M Balwit; Francesco M Marincola
Journal:  J Transl Med       Date:  2010-12-07       Impact factor: 5.531

6.  Defining the critical hurdles in cancer immunotherapy.

Authors:  Bernard A Fox; Dolores J Schendel; Lisa H Butterfield; Steinar Aamdal; James P Allison; Paolo Antonio Ascierto; Michael B Atkins; Jirina Bartunkova; Lothar Bergmann; Neil Berinstein; Cristina C Bonorino; Ernest Borden; Jonathan L Bramson; Cedrik M Britten; Xuetao Cao; William E Carson; Alfred E Chang; Dainius Characiejus; A Raja Choudhury; George Coukos; Tanja de Gruijl; Robert O Dillman; Harry Dolstra; Glenn Dranoff; Lindy G Durrant; James H Finke; Jerome Galon; Jared A Gollob; Cécile Gouttefangeas; Fabio Grizzi; Michele Guida; Leif Håkansson; Kristen Hege; Ronald B Herberman; F Stephen Hodi; Axel Hoos; Christoph Huber; Patrick Hwu; Kohzoh Imai; Elizabeth M Jaffee; Sylvia Janetzki; Carl H June; Pawel Kalinski; Howard L Kaufman; Koji Kawakami; Yutaka Kawakami; Ulrich Keilholtz; Samir N Khleif; Rolf Kiessling; Beatrix Kotlan; Guido Kroemer; Rejean Lapointe; Hyam I Levitsky; Michael T Lotze; Cristina Maccalli; Michele Maio; Jens-Peter Marschner; Michael J Mastrangelo; Giuseppe Masucci; Ignacio Melero; Cornelius Melief; William J Murphy; Brad Nelson; Andrea Nicolini; Michael I Nishimura; Kunle Odunsi; Pamela S Ohashi; Jill O'Donnell-Tormey; Lloyd J Old; Christian Ottensmeier; Michael Papamichail; Giorgio Parmiani; Graham Pawelec; Enrico Proietti; Shukui Qin; Robert Rees; Antoni Ribas; Ruggero Ridolfi; Gerd Ritter; Licia Rivoltini; Pedro J Romero; Mohamed L Salem; Rik J Scheper; Barbara Seliger; Padmanee Sharma; Hiroshi Shiku; Harpreet Singh-Jasuja; Wenru Song; Per Thor Straten; Hideaki Tahara; Zhigang Tian; Sjoerd H van Der Burg; Paul von Hoegen; Ena Wang; Marij Jp Welters; Hauke Winter; Tara Withington; Jedd D Wolchok; Weihua Xiao; Laurence Zitvogel; Heinz Zwierzina; Francesco M Marincola; Thomas F Gajewski; Jon M Wigginton; Mary L Disis
Journal:  J Transl Med       Date:  2011-12-14       Impact factor: 5.531

7.  A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Authors:  Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Magdalena Thurin; Giorgio Trinchieri; Ena Wang; Jon Wigginton; Damien Chaussabel; George Coukos; Madhav Dhodapkar; Leif Håkansson; Sylvia Janetzki; Thomas O Kleen; John M Kirkwood; Cristina Maccalli; Holden Maecker; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; A Karolina Palucka; Douglas M Potter; Antoni Ribas; Licia Rivoltini; Dolores Schendel; Barbara Seliger; Senthamil Selvan; Craig L Slingluff; David F Stroncek; Howard Streicher; Xifeng Wu; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Heinz Zwierzina; Francesco M Marincola
Journal:  J Transl Med       Date:  2008-12-23       Impact factor: 5.531

8.  Immune monitoring technology primer: Single Cell Network Profiling (SCNP).

Authors:  Rachael E Hawtin; Alessandra Cesano
Journal:  J Immunother Cancer       Date:  2015-08-18       Impact factor: 13.751

9.  Immune monitoring technology primer: flow and mass cytometry.

Authors:  Holden T Maecker; Alexandre Harari
Journal:  J Immunother Cancer       Date:  2015-09-15       Impact factor: 13.751

Review 10.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Authors:  Sacha Gnjatic; Vincenzo Bronte; Laura Rosa Brunet; Marcus O Butler; Mary L Disis; Jérôme Galon; Leif G Hakansson; Brent A Hanks; Vaios Karanikas; Samir N Khleif; John M Kirkwood; Lance D Miller; Dolores J Schendel; Isabelle Tanneau; Jon M Wigginton; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751
View more
  4 in total

Review 1.  The role of automated cytometry in the new era of cancer immunotherapy.

Authors:  Marco Danova; Martina Torchio; Giuditta Comolli; Andrea Sbrana; Andrea Antonuzzo; Giuliano Mazzini
Journal:  Mol Clin Oncol       Date:  2018-08-20

Review 2.  Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).

Authors:  Tao Wang; Matthew M Yeh; Mark I Avigan; Lorraine Pelosof; Gerald M Feldman
Journal:  AAPS J       Date:  2021-08-16       Impact factor: 4.009

3.  Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile.

Authors:  Rania H Younis; Ioana Ghita; Manar Elnaggar; Risa Chaisuparat; Vasileios Ionas Theofilou; Donita Dyalram; Robert A Ord; Eduardo Davila; Luke J Tallon; John C Papadimitriou; Tonya J Webb; Søren M Bentzen; Joshua E Lubek
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

Review 4.  Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.

Authors:  Brian Gastman; Piyush K Agarwal; Adam Berger; Genevieve Boland; Stephen Broderick; Lisa H Butterfield; David Byrd; Peter E Fecci; Robert L Ferris; Yuman Fong; Stephanie L Goff; Matthew M Grabowski; Fumito Ito; Michael Lim; Michael T Lotze; Haider Mahdi; Mokenge Malafa; Carol D Morris; Pranav Murthy; Rogerio I Neves; Adekunle Odunsi; Sara I Pai; Sangeetha Prabhakaran; Steven A Rosenberg; Ragheed Saoud; Jyothi Sethuraman; Joseph Skitzki; Craig L Slingluff; Vernon K Sondak; John B Sunwoo; Simon Turcotte; Cecilia Cs Yeung; Howard L Kaufman
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 12.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.